Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ivacaftor

- PMLiVE

Buyers’ Club wants government support on Orkambi imports

Proposes three point plan to work round impasse

- PMLiVE

Vertex eyes Duchenne market with Exonics, CRISPR deals

Biotech has gene-editing expertise

- PMLiVE

Orkambi buyers’ club set up to gain access to cheaper versions

Legal to import generics from abroad

- PMLiVE

Vertex makes choice for all-important CF triple therapy

Promises to treat up to 90% of CF patients

- PMLiVE

NHS England wants money-back guarantee on Orkambi

Vertex resisting real-world data proposal

- PMLiVE

Still no breakthrough on Orkambi talks, MPs want answers

As other price deals go through, Orkambi stalled again

- PMLiVE

Akcea steals march on Alnylam with NICE approval

Advantage to Tegsedi over Onpattro

Vertex: a vision of treating all CF patients worldwide draws closer

Its high prices are controversial, but Vertex also embodies the best of biopharma drug development

- PMLiVE

NICE says no to Novartis’ Kisqali combo in breast cancer

Double blow after Lilly rival recommended

The Orkambi row explained

Q&A and timeline

- PMLiVE

The Orkambi blame game

Grilling by MPs sheds some light on long-running row over CF drug

- PMLiVE

#OrkambiNow?

After a long standoff over CF treatment Orkambi, is a deal imminent?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links